OS Therapies - OSTX Operatsion marja

OSTX (OS Therapies Inc.) - kompaniyaning tovar belgisi

OS Therapies Incorporated (OSTX) ixtisoslashtirilgan onkologiya markazlari bilan hamkorlikda agressiv suyak o'smiklariga qarshi vaksinalarni ishlab chiqadi. Operatsion marja jarayonning moliyaviy tebranishlarini aks ettiradi, bunda ko'rsatkich qiymati 0.00 ga yetadi. Yechim bolalar saratoni bilan kurashish uchun noyob bakterial vektorlarni, shuningdek, preklinik skriningni va hujayra kulturalarini tasdiqlashni tezlashtiruvchi robotlashtirilgan manipulatorlarni joriy etishni o'z ichiga oladi.

ostherapies.com (OSTX): Operatsion foyda normasi 02.08.2024dan 20.11.2026gacha

OS Therapies Incorporated (OSTX) - koʻrsatkichlar kesimi va moliyaviy hisobotlar

- aksiya narxi va baholash bo'yicha konsensus prognoz:
- emitentning bozor qiymati haqida ma'lumotlar:
Kompaniyaning dastlabki tahlili:ostherapies.com, OSTX
OS Therapies, Inc. asosiy tovari

Hozirda onkologiya rivojlantirishining kapital talab qiluvchi R&D bosqichida bo'lgan OS Therapies Incorporated (OSTX) uchun choraklik operatsion marja ventura kapitalini boshqarish samaradorligini aks ettiradi. Ushbu ko'rsatkich operatsion daromadning tushumga nisbati sifatida hisoblanadi va biznesning soliqlar hamda qarz majburiyatlarigacha bo'lgan foydani keltirish qobiliyatini o'lchaydi, bu esa klinik sinovlar uchun likvidlikning intensiv iste'mol qilinishi davrida juda muhimdir.

OS Therapies Incorporated raqobatchilari

Operatsion rentabellik BeiGene Ltd|Halozyme Therapeutics - Operatsion foyda marjasi|Sotuvning operatsion marjasi RVMD (Revolution Medicines Corp)|Operatsion foyda koeffitsiyenti AAPG|Operatsion rentabellik CG Oncology Therapeutics CGON|Operatsion foyda normasi URGN|BCAX: Sotuvning operatsion marjasi|PSNL: Operatsion rentabellik|Erasca (ERAS) - Operatsion rentabellik|DCTH - Operatsion faoliyat rentabelligi|YMAB (Y-mAbs Corp) - Operatsion marja|Sotuvning operatsion marjasi Aura Biosciences (AURA)|Operatsion rentabellik Candel Therapeutics Inc. (CADL)|Sotuvning operatsion marjasi Accuray, Inc. ARAY|Operatsion rentabellik sellaslifesciences.com SLS|Operatsion foyda normasi ACTU|CTOR - Operatsion rentabellik|Operatsion faoliyat rentabelligi tuhurabio.com HURA|Protara Therapeutics, Inc. (TARA) - Operatsion rentabellik|FATE: Operatsion foyda koeffitsiyenti|WHWK (Aadi Bioscience, Inc.) - Operatsion marja|TCRX (TScan Therapeutics) - Operatsion foyda koeffitsiyenti|Operatsion rentabellik Champions Oncology (CSBR)|Operatsion faoliyat rentabelligi XBiotech USA|Operatsion rentabellik CEL-SCI CVM|RADX: Operatsion foyda bo'yicha sotuv rentabelligi|ARTV: Sotuvning operatsion marjasi|ANL (Adlai Nortye) - Operatsion foyda bo'yicha sotuv rentabelligi|Veru (VERU) - Operatsion rentabellik|Sotuvning operatsion marjasi Tempest Therapeutics Inc|Operatsion rentabellik Xilio Therapeutics|Operatsion foyda bo'yicha sotuv rentabelligi RENB (Renovaro Inc.)|Operatsion rentabellik Mural Oncology PLC (MURA)|Operatsion marja Kairos Pharma (KAPA)|Operatsion rentabellik onkuretherapeutics.com OKUR|GDTC: Operatsion foyda bo'yicha sotuv rentabelligi|CRIS: Sotuvning operatsion marjasi|apollomicsinc.com (APLM) - Sotuvning operatsion marjasi|THAR: Operatsion marja|Sotuvning operatsion marjasi Advanced Biomed Inc.|Sotuvning operatsion marjasi GNPX|Operatsion foyda bo'yicha sotuv rentabelligi CLDI (Calidi Biotherapeutics)|Operatsion marja SBFM|Xenetic Biosciences, Inc. - Operatsion foyda bo'yicha sotuv rentabelligi|Operatsion rentabellik Salarius Pharmaceuticals SLRX|Operatsion marja purple-biotech.com PPBT|AONC - Operatsion rentabellik|BGNE: Operatsion rentabellik|CKPT: Operatsion marja|Elevation Oncology - Operatsion foyda normasi|ICAD (iCAD) - Operatsion marja|IKNA: Operatsion foyda normasi|Operatsion rentabellik Notable Labs (NTBL)|VIRX (Viracta Therapeutics, Inc.) - Operatsion foyda normasi|Operatsion rentabellik MorphoSys Corporation MOR|NAYA: Operatsion foyda bo'yicha sotuv rentabelligi|Ascentage Pharma Group International - Operatsion marja